News · 26 weeks25+100%
2026-03-012026-08-23
Mix1690d
- SEC Filings9(56%)
- Other6(38%)
- Earnings1(6%)
Latest news
25 items- SECSEC Form EFFECT filed by SiNtx Technologies Inc.EFFECT - Sintx Technologies, Inc. (0001269026) (Filer)
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity RequirementSALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders’ equity of $2.5 million. Based on SINTX’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately $4.83 million
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- SECSEC Form 10-Q filed by SiNtx Technologies Inc.10-Q - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth InitiativesSALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technolo
- PRSINTX Technologies Announces Second Quarter 2026 Earnings Release Date and WebcastSALT LAKE CITY, Utah, July 28, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m. ET to review the Company’s second quarter 2026 performance. Management participants will include Eric Olson, Chief Executive Officer and Chairman of the Board, and Kevin Trask, Chief Financial Officer. Interested parties may access the conference call and webcast as follows: Webc
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management ProgramSALT LAKE CITY, Utah, July 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced biomaterials and silicon nitride technologies for medical device and industrial applications, today announced that it has engaged Southern Metrics Consulting ("Southern Metrics") to assist the Company in identifying, evaluating, and pursuing strategic opportunities intended to enhance stockholder value. Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025. Southern Metrics will establish and manage the Co
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- SECSEC Form EFFECT filed by SiNtx Technologies Inc.EFFECT - Sintx Technologies, Inc. (0001269026) (Filer)
- SECSEC Form S-3 filed by SiNtx Technologies Inc.S-3 - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase OrdersSALT LAKE CITY, Utah, June 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it has received purchase orders from multiple contract manufacturing customers with an aggregate value exceeding $3.2 million for the production of advanced ceramic components. SINTX’s advanced ceramic manufacturing platform supports customers across multiple industries requiring high-performance materials with demanding mechanical, thermal, and chemical properties. The Company’s expertise in silicon nitride technologies positions it to support both proprietary produ
- SECSEC Form SCHEDULE 13G filed by SiNtx Technologies Inc.SCHEDULE 13G - Sintx Technologies, Inc. (0001269026) (Subject)
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq RulesSALT LAKE CITY, Utah, June 03, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today announced that it has entered into securities purchase agreements with institutional and accredited investors pursuant to which the Company agreed to issue and sell an aggregate of 1,882,845 shares of common stock in a private placement priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors (i) Class A Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock and (ii) Class B Comm
- SECSiNtx Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Sintx Technologies, Inc. (0001269026) (Filer)
- SECSEC Form 10-Q filed by SiNtx Technologies Inc.10-Q - Sintx Technologies, Inc. (0001269026) (Filer)
- INSIDERSEC Form 4 filed by Elmore Robert Ryan4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- ANALYSTH.C. Wainwright initiated coverage on SINTX Technologies with a new price targetH.C. Wainwright initiated coverage of SINTX Technologies with a rating of Buy and set a new price target of $10.00
- PRSINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial ExecutionClinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us
- SECSEC Form 10-K filed by SiNtx Technologies Inc.10-K - Sintx Technologies, Inc. (0001269026) (Filer)
- PRSINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle ImplantMajor clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, today announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market. The procedure represents SINTX's entry int
- INSIDERSEC Form 4 filed by SiNtx Technologies Inc.4 - Sintx Technologies, Inc. (0001269026) (Issuer)
- INSIDERDirector Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)4 - Sintx Technologies, Inc. (0001269026) (Issuer)
SINT FAQ
7 questionsWhat does SiNtx Technologies Inc. do?
Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. It has a collaboration agreement with Oxford Performance Materials, Inc. to develop a poly-ether-ketone-ketone silicon nitride composite based on OXPEKK SC solution casting technology. The company...Where does SINT stock trade?
SiNtx Technologies Inc. (SINT) is listed on NASDAQ.What sector and industry is SINT in?
SiNtx Technologies Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did SiNtx Technologies Inc. go public?
SiNtx Technologies Inc. (SINT) completed its IPO in 2014.What are analysts saying about SINT?
SiNtx Technologies Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1000.00 price target on 2026-04-13. Recent price targets cluster around $1000.00.What companies are similar to SINT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare SINT side-by-side with any of them on Quantisnow.How can I track SINT on Quantisnow?
Quantisnow aggregates SiNtx Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SINT to receive live email and push alerts on every new disclosure.